SNDX Syndax Pharmaceuticals
- 19.060
- -0.820-4.12%
- 19.330
- +0.270+1.42%
Syndax Pharmaceuticals News
Syndax Pharmaceuticals(SNDX.US) Officer Buys US$25,037.25 in Common Stock
$Syndax Pharmaceuticals(SNDX.US)$ Officer Goldan Keith A. purchased 1,250 shares of common stock on Jun 14, 2024 at an average price of $20.0298 for a total value of $25,037.25.Source: Announcement Wh
Express News | Syndax Pharmaceuticals Inc: 52% Crc (14 of 27 Pts) Observed in Augment-102 Trial
Express News | Syndax Pharmaceuticals Inc: 96% Crc (23 of 24 Pts) Observed in Beat Aml Trial
Express News | Syndax Pharmaceuticals Inc: Plans to Initiate a Pivotal Trial With This Combination in Front-Line Newly Diagnosed Patients by Year-End 2024
Express News | Syndax Presents Updated Positive Data From Beat Aml and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients With Acute Leukemias at Eha 2024 Congress
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating
BofA Securities analyst Jason Zemansky maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 67.9% and a total average return of 3
Express News | Syndax Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $31 From $29
Express News | Pyxis Oncology Expands Board of Directors With Appointment of Michael a. Metzger
BTIG Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $35
BTIG analyst Justin Zelin maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 38.2% and a
Syndax Pharmaceuticals to Progress Into Phase 1b Segment of Revumenib Trial
Syndax Pharmaceuticals (SNDX) said Thursday it has advanced into the phase 1b segment of its phase 1/2 proof-of-concept trial of revumenib as a monotherapy for patients with relapsed or refractory met
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $41
H.C. Wainwright analyst Edward White maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of
Express News | Syndax's Revumenib To Enter Phase 1b For Metastatic Colorectal Cancer After IDMC Endorsement
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., June 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced t
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of Ooma, Inc. (NYSE:OOMA) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and issued strong guidance for the second qu
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $32
Barclays analyst Peter Lawson maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 44.1% a
Express News | JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Maintains $34 Price Target
Express News | Syndax Pharmaceuticals Inc : JP Morgan Adds Stock to Its U.S. Analyst Focus List
Syndax Pharmaceuticals Welcomes New Board Member, Passes Resolutions
Express News | Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.d., Ph.d. to the Board of Directors
Analysis
Price Target
No Data
